These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 28936936)
1. [Treatment of dementia]. Blom K; van den Elsen GAH; Koek HL; Sanders JB; Kruithof HC; Claassen JAHR Ned Tijdschr Geneeskd; 2017; 161():D1851. PubMed ID: 28936936 [TBL] [Abstract][Full Text] [Related]
2. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561 [TBL] [Abstract][Full Text] [Related]
3. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Kavirajan H; Schneider LS Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia. Versijpt J J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049 [TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. Wong CW Drugs Aging; 2016 Jul; 33(7):451-60. PubMed ID: 27154396 [TBL] [Abstract][Full Text] [Related]
8. [Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook]. Hausner L; Frölich L Dtsch Med Wochenschr; 2019 Feb; 144(3):156-160. PubMed ID: 30703832 [TBL] [Abstract][Full Text] [Related]
9. [How Treatable is Vascular Dementia?]. Mori E Brain Nerve; 2016 Apr; 68(4):441-50. PubMed ID: 27056862 [TBL] [Abstract][Full Text] [Related]
10. [Drug treatment of Alzheimer's dementia : Status quo and perspectives]. Müller P; Fendt M; Müller NG Internist (Berl); 2019 Jul; 60(7):761-768. PubMed ID: 31139854 [TBL] [Abstract][Full Text] [Related]
11. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. Small G; Erkinjuntti T; Kurz A; Lilienfeld S CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529 [TBL] [Abstract][Full Text] [Related]
12. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. Sonkusare SK; Kaul CL; Ramarao P Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine. Desmidt T; Hommet C; Camus V Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):300-6. PubMed ID: 27651011 [TBL] [Abstract][Full Text] [Related]
14. Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias. Balázs N; Bereczki D; Kovács T Ideggyogy Sz; 2021 Nov; 74(11-12):379-387. PubMed ID: 34856086 [TBL] [Abstract][Full Text] [Related]
15. [Cholesterol inhibitor and memantine in symptomatic dementia therapy]. Rodda J; Carter J Praxis (Bern 1994); 2013 Feb; 102(5):293-300; discussion 298-9. PubMed ID: 23446240 [No Abstract] [Full Text] [Related]
16. Diagnosis and treatment of cognitive impairment. von Arnim CAF; Bartsch T; Jacobs AH; Holbrook J; Bergmann P; Zieschang T; Polidori MC; Dodel R Z Gerontol Geriatr; 2019 Jul; 52(4):309-315. PubMed ID: 31161337 [TBL] [Abstract][Full Text] [Related]
18. Use of memantine for the treatment of dementia. Lo D; Grossberg GT Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US. Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535 [TBL] [Abstract][Full Text] [Related]